keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatology;biologics

keyword
https://www.readbyqxmd.com/read/28542043/induction-therapy-with-biosimilar-infliximab-in-children-with-crohn-s-disease
#1
Joanna Sieczkowska-Golub, Monika Meglicka, Anna Plocek, Aleksandra Banaszkiewicz, Dorota Jarzębicka, Ewa Toporowska-Kowalska, Agnieszka Gawronska, Grzegorz Oracz, Jaroslaw Kierkus
INTRODUCTION: In most European countries, an infliximab biosimilar (CT-P13) is currently in common use. In vitro and in vivo studies have proved a high similarity between CT-P13 and the reference infliximab. CT-P13 was licensed for use in patients with Crohn's diseases (CD) based on the extrapolation of data from preclinical studies and clinical trials in rheumatology indications. The aim of this study was to assess the similarity between CT-P13 and the originator infliximab in induction therapy in CD paediatric patients...
May 24, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28535544/portuguese-recommendations-for-the-use-of-biological-therapies-in-patients-with-rheumatoid-arthritis-2016-update
#2
Catia Duarte, Joana Sousa-Neves, Ana Águeda, Pedro Ribeiro, Alexandra Daniel, Gisela Eugénio, Sofia Serra, Filipe Araújo, Anabela Barcelos, Barcelos Filipe, Miguel Bernardes, Helena Canhão, Marcos Cerqueira, Susana Capela, Ana Cordeiro, Flavio Costa, Lucia Costa, Margarida Cruz, Luis Cunha Miranda, Catarina Duarte, Sandra Falcão, Daniela Faria, Ricardo Figueira, João Pedro Freitas, Maria João Gonçalves, João Madruga Dias, José Melo Gomes, Ana Filipa Mourão, Adriano Neto, Filipa Oliveira Ramos, Sofia Pimenta, Patricia Pinto, Joaquim Polido Pereira, Cristina Ponte, João Ramos, Ana Rodrigues, Helena Santos, Maria José Santos, Alexandre Sepriano, Candida Silva, José Tavares Costa, Filipa Teixeira, Vitor Teixeira, Paula Valente, Elsa Vieira-Sousa, Rita Barros, Pedro Abreu, João Eurico Fonseca
OBJECTIVE: To update the recommendations for the treatment of Rheumatoid Arthritis (RA) with biological therapies, endorsed by the Portuguese Society of Rheumatology (SPR). METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. At a national meeting the 10 recommendations were discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the recommendations...
May 4, 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28532819/il-23-th17-targeted-therapies-in-sapho-syndrome-a-case-series
#3
Daniel Wendling, François Aubin, Frank Verhoeven, Clément Prati
SAPHO syndrome is a rare entity with skin and rheumatologic inflammatory presentation. The treatment is not standardized, and in case of inadequate response to anti inflammatory drugs, the use of anti TNF or anti IL-1 biologic treatments has been reported. The IL-23/Th17 axis may be involved in SAPHO syndrome. We report the results of six courses of IL-23 and IL-17 targeted therapies (3 ustekinumab and 3 secukinumab) in patients with SAPHO syndrome unresponsive to previous treatments (csDMARDs and bDMARDs)...
May 19, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28529116/italian-consensus-guidelines-for-the-management-of-hepatitis-b-virus-infections-in-patients-with-rheumatoid-arthritis
#4
Marco Sebastiani, Fabiola Atzeni, Laura Milazzo, Luca Quartuccio, Carlo Scirè, Giovanni Battista Gaeta, Giovanni Lapadula, Orlando Armignacco, Marcello Tavio, Ignazio Olivieri, Pierluigi Meroni, Laura Bazzichi, Walter Grassi, Alessandro Mathieu, Claudio Mastroianni, Evangelista Sagnelli, Teresa Santantonio, Caterina Uberti Foppa, Massimo Puoti, Loredana Sarmati, Paolo Airò, Oscar Massimiliano Epis, Rossana Scrivo, Miriam Gargiulo, Agostino Riva, Andreina Manfredi, Giovanni Ciancio, Gianguglielmo Zehender, Gloria Taliani, Luca Meroni, Salvatore Sollima, Piercarlo Sarzi-Puttini, Massimo Galli
OBJECTIVES: Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid arthritis (RA). The Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) endorsed a national consensus process to review the available evidence on HBV management in RA patients and to produce practical, hospital-wide recommendations. METHODS: The consensus panel consisted of infectious disease consultants, rheumatologists and epidemiologists and used the criteria of the Oxford Centre for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations...
May 18, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28516869/recommendations-for-infectious-disease-screening-in-migrants-to-western-europe-with-inflammatory-arthropathies-before-starting-biologic-agents-results-from-a-multidisciplinary-task-force-of-four-european-societies-sir-ser-simet-semtsi-facing-the-lar
#5
Filippo Bartalesi, Carlo Scirè, Ana Requena-Méndez, Miguel Angel Abad, Dora Buonfrate, Roberto Caporali, Fabrizio Conti, Federico Diaz-Gonzalez, Cruz Fernández-Espartero, Carmen Martinez-Fernandez, Marta Mascarello, Elena Generali, Giovanni Minisola, Aldo Morrone, Jose Muñoz, Patricia Richi, Gariffalia Sakellariou, Joaquin Salas Coronas, Michele Spinicci, Francesco Castelli, Alessandro Bartoloni, Zeno Bisoffi, Francisco Gimenez-Sanchez, Santiago Muñoz-Fernandez, Marco Matucci-Cerinic
OBJECTIVES: Inflammatory arthritis needs infectious disease screening before starting a biologic agent, however, few data are known about migrant patients, who represent a peculiar population which requires a multidisciplinary approach among international health specialists and should also be considered by health authorities. For this reason, the Italian and Spanish Societies of Rheumatology (SIR and SER) and Tropical Medicine (SIMET and SEMTSI) promoted a multidisciplinary task force in order to produce specific recommendations about screening and advices to be considered in migrant patients with inflammatory arthritis candidate to receive biological therapy, according to their geographical origin...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516236/identification-of-patients-at-risk-of-non-adherence-to-oral-antirheumatic-drugs-in-rheumatoid-arthritis-using-the-compliance-questionnaire-in-rheumatology-an-arco-sub-study
#6
Carlos Marras, Indalecio Monteagudo, Georgina Salvador, Francisco J de Toro, Alejandro Escudero, Juan J Alegre-Sancho, Enrique Raya, Ana Ortiz, Loreto Carmona, Yvonne Mestre, Luis Cea-Calvo, Jaime Calvo-Alén
The ARCO study (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs), a multicenter, non-interventional retrospective study, was primarily designed to assess the percentage of patients [aged ≥18 years with an established rheumatoid arthritis (RA) diagnosis] with non-adherence to prescribed subcutaneous biologicals. This paper reports data for the secondary objective from a subset of patients, namely to evaluate non-adherence to prescribed oral antirheumatic drugs in RA patients in Spain using the validated Compliance Questionnaire Rheumatology (CQR)...
May 17, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28512006/stress-fracture-in-athletes
#7
Jordane Saunier, Roland Chapurlat
Stress fractures are widely encountered in sport medicine and rheumatology. Stress fractures result from abnormal and repetitive loading on normal bone that lead to microdamage and then fracture. They occur after sudden increase in physical activity. They appear mostly at lower limbs. Women are at higher risk than men. Patients complain of mechanical pain. Clinical findings include focused pain and sometimes swelling. No biological test is useful for diagnosis. Plain radiographs are normal in early stage disease...
May 13, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28511689/harnessing-interactive-technologies-to-improve-health-outcomes-in-juvenile-idiopathic-arthritis
#8
REVIEW
Andrea Coda, Dean Sculley, Derek Santos, Xavier Girones, Lucie Brosseau, Derek R Smith, Joshua Burns, Keith Rome, Jane Munro, Davinder Singh-Grewal
BACKGROUND: Children and adolescents with Juvenile Idiopathic Arthritis (JIA) typically have reduced physical activity level and impaired aerobic and anaerobic exercise capacity when compared to their non-JIA counterparts. Low intensity exercise regimens appear to be safe in children with JIA and may results in improvements in overall physical function. Poor adherence to paediatric rheumatology treatment may lead to negative clinical outcomes and possibly increased disease activity. This includes symptoms such as pain, fatigue, quality of life, longer term outcomes including joint damage, as well as increase of healthcare associated costs...
May 16, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28511684/access-to-pediatric-rheumatology-care-for-juvenile-idiopathic-arthritis-in-the-united-arab-emirates
#9
Khulood Khawaja, Mustafa Al-Maini
BACKGROUND: This study looks at access to care for Juvenile Idiopathic Arthritis through pediatric rheumatology in the UAE, as an example of multi-ethnic society. METHODS: Patients with a diagnosis of Juvenile idiopathic arthritis were identified through the hospital electronic medical records system from January 1st 2011 to December 31st 2014. All residents of the United Arab Emirates hold an Emirates identity card. We divided our patients into two groups: Emirati-Emirates, who are native Emirati children and hold the Emirati nationality, as stated on their Emirates identity card, and who therefore have full, comprehensive access to free medical care; and non-Emirati-Emirates, who represent other nationalities, as stated on their Emirates identity card...
May 16, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28485187/tumour-necrosis-factor-%C3%AE-etanercept-complexes-in-serum-predict-long-term-efficacy-of-etanercept-treatment-in-seronegative-rheumatoid-arthritis
#10
E Berthold, B Månsson, B Gullstrand, P Geborek, T Saxne, A A Bengtsson, R Kahn
OBJECTIVE: To study whether serum levels of tumour necrosis factor-α (TNF-α), free or bound to etanercept, in biological-naïve adults with rheumatoid arthritis (RA) could predict the long-term efficacy of etanercept, measured as drug survival. METHOD: We identified 145 biological-naïve patients with RA starting treatment with etanercept at the Department of Rheumatology, Skåne University Hospital (1999-2008), of whom 16 had seronegative and 129 seropositive RA...
May 9, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28481462/biologics-or-tofacitinib-for-people-with-rheumatoid-arthritis-naive-to-methotrexate-a-systematic-review-and-network-meta-analysis
#11
REVIEW
Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell, George A Wells
BACKGROUND: Biologic disease-modifying anti-rheumatic drugs (biologics) are highly effective in treating rheumatoid arthritis (RA), however there are few head-to-head biologic comparison studies. We performed a systematic review, a standard meta-analysis and a network meta-analysis (NMA) to update the 2009 Cochrane Overview. This review is focused on the adults with RA who are naive to methotrexate (MTX) that is, receiving their first disease-modifying agent. OBJECTIVES: To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (methotrexate (MTX)/other DMARDs) in people with RA who are naive to methotrexate...
May 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28476652/lipoprotein-a-concentrations-in-rheumatoid-arthritis-on-biologic-therapy-results-from-the-cardiovascular-in-rheumatology-study-project
#12
Carmen García-Gómez, Maria A Martín-Martínez, Santos Castañeda, Fernando Sanchez-Alonso, Miren Uriarte-Ecenarro, Carlos González-Juanatey, Montserrat Romera-Baures, José Santos-Rey, José Antonio Pinto-Tasende, Estefanía Quesada-Masachs, Jesús Tornero-Molina, Olga Martínez-González, Tatiana Cobo-Ibáñez, Eugenio Chamizo-Carmona, Sara Manrique-Arija, Dolores Fábregas-Canales, Federico Díaz-González, Javier Llorca, Miguel A González-Gay
BACKGROUND: Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved. OBJECTIVE: The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics...
March 16, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28464558/prescribing-for-children-with-rheumatologic-disease-perceived-treatment-approaches-between-pediatric-and-adult-rheumatologists
#13
Heather Van Mater, Stephen J Balevic, Gary L Freed, Sarah J Clark
OBJECTIVE: To compare practice patterns and prescribing differences for juvenile idiopathic arthritis (JIA) between adult and pediatric rheumatologists, the perceived educational needs, and factors that enhance or impede co-management. METHODS: Two parallel, cross sectional surveys focusing on JIA were administered in 2009 to a random sample of 193 pediatric rheumatologists (PR) and 500 adult rheumatologists (AR) using the American College of Rheumatology membership file...
May 2, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28461649/canadian-rheumatology-association-meeting-the-westin-ottawa-ottawa-ontario-canada-february-8-11-2017
#14
Earl D Silverman
The 72nd Annual Meeting of The Canadian Rheumatology Association (CRA) was held at The Westin Ottawa, Ottawa, Ontario, Canada, February 8-11, 2017. The program consisted of presentations covering original research, symposia, awards, and lectures. Highlights of the meeting include the following 2017 award winners: Dr. Vinod Chandran, Young Investigator; Dr. Jacques P. Brown, Distinguished Investigator; Dr. David Robinson, Teacher-Educator; Dr. Michel Zummer, Distinguished Rheumatologist; Ms. Rebecca Gole, Best Abstract on SLE Research by a Trainee - Ian Watson Award; Ms...
May 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28461199/new-structural-formats-of-therapeutic-antibodies-for-rheumatology
#15
Christophe Dumet, Jérémy Pottier, Valérie Gouilleux, Hervé Watier
Pharmaceutical companies strive continuously to develop better medications in order to remain competitive. In the arena of monoclonal antibodies and related biologics (fusion proteins containing an IgG Fc fragment), the thrust is not only toward identifying new targets, but also toward developing new molecular formats. Here, new-generation antibodies used to treat rheumatic diseases are discussed, with emphasis on relations linking structure to pharmacological effects and on the improvements expected from the new formats...
April 28, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28457525/retrospective-study-evaluating-treatment-decisions-and-outcomes-of-childhood-uveitis-not-associated-with-juvenile-idiopathic-arthritis
#16
Elham Sardar, Perrine Dusser, Antoine Rousseau, Bahram Bodaghi, Marc Labetoulle, Isabelle Koné-Paut
OBJECTIVE: To evaluate treatment, ocular complications and outcomes of children with pediatric uveitis not associated with juvenile idiopathic arthritis. STUDY DESIGN: This was a retrospective chart review of pediatric uveitis in children under 16 years of age, recruited from the pediatric rheumatology department at Bicêtre Hospital from 2005 to 2015. Patients with juvenile idiopathic arthritis-associated and infectious uveitis were excluded. We used the Standardization of Uveitis Nomenclature Working Group to classify uveitis, disease activity, and treatment end points...
April 27, 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/28450312/long-term-outcome-is-better-when-a-methotrexate-based-treatment-strategy-is-combined-with-10-mg-prednisone-daily-follow-up-after-the-second-computer-assisted-management-in-early-rheumatoid-arthritis-trial
#17
Mary Safy, Jwg Jacobs, N D IJff, Jwj Bijlsma, J M van Laar, Mjh deHair
OBJECTIVES: In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD), radiographic outcome and onset of glucocorticoid (GC)-related comorbidities...
April 27, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28435230/persistence-with-golimumab-in-immune-mediated-rheumatic-diseases-a-systematic-review-of-real-world-evidence-in-rheumatoid-arthritis-axial-spondyloarthritis-and-psoriatic-arthritis
#18
REVIEW
Axel Svedbom, Chiara Storck, Sumesh Kachroo, Marinella Govoni, Ahmed Khalifa
PURPOSE: In immune-mediated rheumatic diseases (IMRDs), persistence to treatment may be used as a surrogate marker for long-term treatment success. In previous comparisons of persistence to tumor necrosis factor α inhibitors (TNFis), a paucity of data for subcutaneous (SC) golimumab was identified. The aim of this study was to conduct a systematic review of persistence to SC golimumab in clinical practice and contextualize these data with five-year persistence estimates from long-term open-label extension (OLE) trials of SC TNFis in IMRDs...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28434948/international-and-multidisciplinary-expert-recommendations-for-the-use-of-biologics-in-systemic-lupus-erythematosus
#19
REVIEW
Jean-François Kleinmann, Florence Tubach, Véronique Le Guern, Alexis Mathian, Christophe Richez, David Saadoun, Karim Sacre, Jérémie Sellam, Raphaèle Seror, Zahir Amoura, Emmanuel Andres, Sylvain Audia, Brigitte Bader-Meunier, Gilles Blaison, Bernard Bonnotte, Patrice Cacoub, Sophie Caillard, Laurent Chiche, Olivier Chosidow, Nathalie Costedoat-Chalumeau, Claire Daien, Eric Daugas, Nairouz Derdèche, Andrea Doria, Olivier Fain, Fadi Fakhouri, Dominique Farge, Cem Gabay, Sylvie Guillo, Eric Hachulla, Najia Hajjaj-Hassouni, Mohamed Hamidou, Frédéric A Houssiau, Noémie Jourde-Chiche, Isabelle Koné-Paut, Aïcha Ladjouz-Rezig, Olivier Lambotte, Dan Lipsker, Xavier Mariette, Nicolas Martin-Silva, Thierry Martin, François Maurier, Roderich Meckenstock, Arsène Mékinian, Olivier Meyer, Shirine Mohamed, Jacques Morel, Bruno Moulin, Denis Mulleman, Thomas Papo, Vincent Poindron, Xavier Puéchal, Leonardo Punzi, Pierre Quartier, Laurent Sailler, Amar Smail, Martin Soubrier, Agnès Sparsa, Zoubida Tazi-Mezalek, Leith Zakraoui, Stéphane Zuily, Jean Sibilia, Jacques-Eric Gottenberg
BACKGROUND/PURPOSE: Despite conventional immunosuppressants, active and steroid-dependent systemic lupus erythematosus (SLE) represents a therapeutic challenge. Only one biologic, belimumab, has been approved, but other biologics are sometimes used off-label. Given the lack of evidence-based data in some clinical situations encountered in real life, we developed expert recommendations for the use of biologics for SLE. METHODS: The recommendations were developed by a formal consensus method...
April 18, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28416023/the-new-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-design-rationale-and-characteristics-of-patients-enrolled-in-the-first-12%C3%A2-months
#20
Timothy Beukelman, Yukiko Kimura, Norman T Ilowite, Kelly Mieszkalski, Marc D Natter, Grendel Burrell, Brian Best, Jason Jones, Laura E Schanberg
BACKGROUND: Herein we describe the history, design, and rationale of the new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry and present the characteristics of patients with juvenile idiopathic arthritis (JIA) enrolled in the first 12 months of operation. METHODS: The CARRA Registry began prospectively collecting data in the United States and Canada in July 2015 to evaluate the safety of therapeutic agents in persons with childhood-onset rheumatic disease, initially restricted to JIA...
April 17, 2017: Pediatric Rheumatology Online Journal
keyword
keyword
47772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"